



Embrace2: Advanced Seizure Detection for Children

Embrace2, the FDA-cleared wearable, provides groundbreaking seizure detection for children ages 6 and up. Its innovative technology is perfectly suited to CSH's commitment to pediatric health.

By working together, we can investigate expanding this life-changing technology to reach even younger children, reinforcing our dedication to exceptional pediatric care.



by Areeb Uzzaman

Embrace2 Technology Overview

1 Advanced Wearable

Wrist-worn device with sophisticated sensors that detect tonic-clonic seizures lasting 20+ seconds.

2 Real-Time Alerts

Instantly notifies caregivers via smartphone when seizure activity is detected.

3 Practical Design

48+ hour battery life with water-resistant construction for everyday wear.



embrace 2
Smarter Epilepsy
Management



FDA-CLEARED

NEW

EpiMonitor, the future of epilepsy monitoring

Our next generation FDA-cleared medical wearable, EpiMonitor, is now available to purchase in the US for adults and children 6+.

DISCOVER EPIMONITOR >



How Embrace2 Works

1

Sensor Technology

Combines accelerometer and electrodermal activity sensors to monitor physiological signals.

2

Smart Detection

Proprietary algorithms identify seizure-like movements with high accuracy.

3

Alert System

Analyzes data in real-time and sends immediate alerts through Empatica's app.

Current Limitations and Opportunities

Current Limitation

FDA clearance only for children ages 6 and older, creating a monitoring gap for younger patients.

Key Opportunity

CSH is uniquely positioned to lead pediatric epilepsy innovation for ages 4-5.

Potential Impact

Reduced emergency room visits and improved quality of life for children with epilepsy.

Proposed CSH-Led Clinical Study

6-Month Study

30 participants ages 4-10 in controlled clinical environment.

Expanding Access

Potential to extend FDA clearance to ages 4+.



Clear Objectives

Evaluate Embrace2 efficacy in younger children.

Key Metrics

Seizure detection accuracy, false alarm rates, ER visit reduction.

Clinical Study and Methodology

1

Participant Selection

Randomized controlled trial with 15 Embrace2 users and 15 controls.

2

Data Collection

Daily seizure logs and monthly neurologist check-ins.

3

Quantitative Analysis

Tracking seizure frequency, duration, and emergency room visits.

4

Qualitative Feedback

Family assessments on usability and peace of mind.



Implementation and Financial Considerations

CHS Patients

The Embrace2 is primarily for individuals aged 6+.

FDA Clearance

Indicates safety and effectiveness for its intended use.

Insurance Coverage

Coverage varies; you'll typically need a prescription. Contact your insurance provider.

Cost

Upfront cost around \$249, plus a monthly subscription fee.

The companion apps are free, but functionality relies on a paid subscription. You can purchase the device directly from Empatica or through insurance. The main goals are timely intervention and peace of mind. Subscription fees can range from roughly \$10 to \$50+ per month depending on the plan chosen (e.g., monthly vs. annual payment).

Potential Co-Branding Approach

Brand Partnership

Leverage CSH's trusted reputation in pediatric care through co-branding with Embrace2.

Educational Materials

Develop co-branded resources for families and physicians on seizure management.

CSH Seizure Safety Kit


Create comprehensive package including Embrace2 and support resources.

Revenue Model

Implement revenue sharing with Empatica for CSH-approved devices.



Anticipated Outcomes and Impact





embrace 2

Smarter Epilepsy
Management

Questions and Discussion



Trial Design

What adjustments would strengthen our research methodology?



Potential Challenges

What obstacles should we prepare for?



Resource Allocation

How should we prioritize funding and staffing?



Long-term Vision

How will this shape CSH's role in pediatric epilepsy care?